MRVI vs. OGN, RARE, PTCT, ADMA, RNA, ZLAB, BHVN, ALVO, SRRK, and IMVT
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Avidity Biosciences (RNA), Zai Lab (ZLAB), Biohaven (BHVN), Alvotech (ALVO), Scholar Rock (SRRK), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs.
Organon & Co. (NYSE:OGN) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Maravai LifeSciences received 45 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 61.76% of users gave Maravai LifeSciences an outperform vote while only 33.96% of users gave Organon & Co. an outperform vote.
In the previous week, Maravai LifeSciences had 30 more articles in the media than Organon & Co.. MarketBeat recorded 36 mentions for Maravai LifeSciences and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.21 beat Maravai LifeSciences' score of -0.14 indicating that Organon & Co. is being referred to more favorably in the media.
Organon & Co. has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Organon & Co. currently has a consensus target price of $20.80, indicating a potential upside of 44.95%. Maravai LifeSciences has a consensus target price of $9.28, indicating a potential upside of 207.33%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Organon & Co..
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Comparatively, 0.6% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Organon & Co. has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500.
Organon & Co. has a net margin of 13.49% compared to Maravai LifeSciences' net margin of -81.13%. Organon & Co.'s return on equity of 431.62% beat Maravai LifeSciences' return on equity.
Summary
Organon & Co. beats Maravai LifeSciences on 13 of the 19 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 3/4/2025 by MarketBeat.com Staff
Free MRVI Stock Alerts